Purple Biotech PPBT 深 沪
等待开盘 08-18 09:30:00 美东时间
2.31
0.000
0.00%
华盛通- 最 高2.40
- 今 开2.30
- 成交量 9692股
- 最 低 2.21
- 昨 收 2.31
- 总市值 611.73万
- 52周最高 13.95
- 市盈率 静 --
- 换手率 0.37%
- 52周最低 2.00
- 委 比 -97.44%
- 总股本 264.82万
- 历史最高 1390.00
- 量 比 0.60
- 振 幅 8.23%
- 历史最低 2.07
- 每 手 1
- 风险率 1.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Purple Biotech GAAP EPADS of -$0.57
Purple Biotech press release (NASDAQ:PPBT): Q2 GAAP EPADS of -$0.57. As of June 30, 2025, Purple Biotech had cash and cash equivalents and short-term deposits of $5.6 million. The Company cash runway ...
08-06 19:44
Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025
In the first half of 2025, Purple Biotech Ltd. made significant progress in advancing its core programs. CM24 demonstrated strong efficacy in biomarker-enriched subgroups of second-line PDAC patients, with an ORR of 37.5% and 31%, compared to 0% in the control group. Phase 2 results showed improved PFS and OS in these subgroups. The company plans to advance CM24 into a biomarker-driven Phase 2b study. CAPTN-3 showcased synergistic activity and po...
07-23 11:00
Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress
<p>REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies to overcome tumor immune evasion and drug resistance, announced the presentation of new preclinical data on its novel CAPTN-3 tri-specific antibody platform at the 2025 Annual Congress of the European Association for Cancer Research (EACR 2025) in Lisbon, Po...
06-23 11:00
Purple Biotech Initiated Phase 2 Study Evaluating NT219 In Patients With Recurrent And/Or Metastatic Squamous Cell Carcinoma Of The Head And Neck
NT219 is a novel small molecule designed to target two key oncogenic pathways: IRS1/2 (Insulin Receptor Substrates 1 and 2) and STAT3 (Signal Transducer and Activator of Transcription 3). NT219 induces the
06-17 19:05
Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer
Purple Biotech Ltd. has initiated a Phase 2 clinical study to evaluate NT219, a novel small molecule targeting IRS1/2 and STAT3 pathways, in combination with pembrolizumab or cetuximab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). The study, led by Dr. Antonio Jimeno at the University of Colorado, is structured into two single-arm cohorts with potential expansion, aiming to assess efficacy and...
06-17 11:00
Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform
Purple Biotech Ltd. announced its participation in the EACR 2025 Congress with a poster presentation on its novel CAPTN-3 tri-specific antibody platform, designed to activate T cells and NK cells for enhanced anti-tumor immune response. The presentation, titled "CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers," will be delivered by Dr. Hadas Reuveni on June 17, 2025, in Lisbon. The abstract (EACR25-1964) highlight...
06-04 11:00
Purple Biotech GAAP EPADS of -$0.17
Purple Biotech press release (NASDAQ:PPBT): Q1 GAAP EPADS of -$0.17. More on Purple Biotech Seeking Alpha’s Quant Rating on Purple Biotech Historical earnings data for Purple Biotech Financial informa...
05-21 19:14
Purple Biotech Q1 EPS $(0.17) Misses $(0.06) Estimate
Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.06) by 183.33 percent. This is a 93.93 percent increase over losses of $(2.80) per share from
05-21 19:14
Purple Biotech Appoints New CFO Amid Strategic Growth
The latest announcement is out from Purple Biotech ( ($PPBT) ). On May 12, 2025...
05-12 19:58
Purple Biotech names Shai Lankry as CFO
Purple Biotech (NASDAQ:PPBT) said it has appointed Shai Lankry as its finance chief. Before joining the company, Lankry supported several companies as a strategic fractional chief financial officer t...
05-12 19:52
